Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

J Exp Ther Oncol. 2011;9(3):183-6.

Abstract

Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / economics*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / economics*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab
  • Central Nervous System Neoplasms / drug therapy*
  • Cost Savings
  • Disease-Free Survival
  • Female
  • Glioblastoma / drug therapy*
  • Humans
  • Infusions, Intra-Arterial / economics
  • Infusions, Intravenous / economics
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab